AUTHORS
Michael Lim, MBBS, MRCP (UK), FRCPath, PhD, Carlos Jimenez-Vicente, MD, PhD2, Anamay Shetty3, Hannah Al-Yousuf, MBBS4, Catharina Tao5, Jelena Jovanovic, PhD6, Manohursingh Runglall7, Phoebe Aucken, BSc8, Amanda Gilkes9, Joanna Canham10, Sean Johnson, PhD11, Ian F. Thomas12, Mathew Sheridan13, Katharine Hodby, PhD, BA, MRCPath14, Priyanka Mehta, MD, FRCPath, MRCP15, Anne-Louise Latif, Mb ChB, PhD16, Dania Muwafy, MBBS17, Renuka Palani18, Eduardo Olavarria, MD, PhD19, Rajani Chengal20, Danah Chakfeh21, Sarah Gangoli22, James Aries23, Mike Dennis, MD24, David C. Taussig, PhD,MRCP,FRCPath25, Muhammad Saif, MD26, Deepak Mannari27, Angela Collins28, Henry Simons29, Eleni Tholouli, MD, PhD30, Omer Pervaiz31, Hans Ommen32, Ulrik Overgaard33, Ruth Spearing34, Paul Cahalin35, Ellen Solomon36, Sylvie D Freeman, MD, PhD37, Steven Knapper, DM, FRCPath, MBBChir38, Andrew King39, Kavita Raj, MD, PhD40, Jad Othman, MD41, Nicola Potter, PhD42, Nigel H. Russell, MD43, Richard Dillon, MBBS44
AFFILIATIONS
1 Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom, King's College London, London, United Kingdom
2 King's College London, London, United Kingdom
3 University College London Hospital, London, United Kingdom
4 University College London Hospital, London, United Kingdom
5 Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
6 King's College London, London, United Kingdom
7 Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom, King's College London, London, United Kingdom
8 King's College London, London, United Kingdom
9 Cardiff University, Cardiff, United Kingdom
10 Cardiff University, Cardiff, United Kingdom
11 Cardiff University, Cardiff, United Kingdom
12 Cardiff University, Cardiff, United Kingdom
13 University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
14 University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
15 University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
16 Queen Elizabeth University Hospital, Glasgow, United Kingdom
17 Imperial College Healthcare NHS Trust, London, United Kingdom
18 Imperial College Healthcare NHS Trust, London, United Kingdom
19 Imperial College Healthcare NHS Trust, London, United Kingdom
20 North West Anglia NHS Foundation Trust, Peterborough, United Kingdom
21 Barts Health NHS Trust, London, United Kingdom
22 Barts Health NHS Trust, London, United Kingdom
23 Barts Health NHS Trust, London, United Kingdom
24 The Christie NHS Foundation Trust, Manchester, United Kingdom
25 The Royal Marsden NHS Foundation Trust, London, United Kingdom
26 The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom
27 Somerset NHS Foundation Trust, Taunton, United Kingdom
28 Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
29 Manchester University NHS Foundation Trust, Manchester, United Kingdom
30 Manchester University NHS Foundation Trust, Manchester, United Kingdom
31 Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom
32 Aarhus University Hospital, Aarhus, Denmark
33 National University Hospital, Copenhagen, Denmark
34 University of Otago, Christchurch, New Zealand
35 Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom
36 King's College London, London, United Kingdom
37 University of Birmingham, Birmingham, United Kingdom
38 Cardiff University, Cardiff, United Kingdom
39 Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
40 University College London Hospital, London, United Kingdom
41 King's College London, London, United Kingdom
42 King's College London, London, United Kingdom
43 Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
44 Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom, King's College London, London, United Kingdom
ABSTRACT
Introduction
NUP98 rearrangements (NUP98r) are associated with approximately 1-5% of adult AML and adverse clinical outcomes. Retrospective analyses of real-world NUP98r AML cohorts have indicated the benefit of allogeneic stem cell transplantation (alloSCT). However, the optimal induction chemotherapy backbone, and the role of measurable residual disease monitoring (MRD) have not been thoroughly assessed. Here, we addressed these questions by combining two large, prospective RCTs and a cohort of real-world patients with NUP98r AML monitored prospectively by molecular MRD.
Methods
The UK NCRI AML17 (2009-2014) and AML19 (2015-2020) studies enrolled younger adults with newly diagnosed AML fit for intensive chemotherapy. NUP98r were identified using cytogenetics, PCR or RNA sequencing (which was performed for patients with apparently isolated FLT3-ITD mutation).
The real-world (RW) cohort included consecutive patients at 16 centres between 2017-2026 and who had undergone prospective molecular MRD monitoring for NUP98 fusion transcripts. This was performed by 2 centralised laboratories by RT-qPCR or digital PCR.
We assessed overall survival (OS) and relapse-free survival (RFS) using landmark log-rank and Mantel-Byar tests.
Results
A total of 84 NUP98r patients (AML17 n=21, AML19 n=24, RW n=39) were identified. NUP98::NSD1 was detected in 61 patients (73%), NUP98::HOX in 10 (12%), and other fusion partners in 13 (15%).
The induction backbone was FLAG-ida in 22 (26%), DA-type in 62 (73%); 31 (37%) received GO. Of the 29 RW patients with either FLT3-ITD or FLT3-TKD mutations, 18 (62%) received a FLT3 inhibitor. CR/CRi was achieved after cycle 1 (C1) in 50/81 (62%), and C2 in 73/84 (87%). 62 (74%) received an alloSCT including 48 (57%) in CR1.
Median follow-up was 32 months, median OS and RFS for the combined cohort was 29 months and 15 months respectively. 3-year OS and RFS were 47% and 30%.
Survival was significantly worse in AML17 compared to AML19 (HR 0.41, 0.19-0.92, p=0.011) and RW cohorts (HR 0.38, 0.19-0.77, p=0.011). Univariate analysis identified no significant difference in OS with induction regimen (FLAG-ida vs DA-type, HR 1.13, 0.54-2.19, p=0.731), or gemtuzumab (GO vs no-GO, HR 0.87, 0.44-1.63, p=0.664).
AlloSCT significantly improved OS (HR 0.45, 0.22-0.92, p=0.028). AlloSCT in first remission (CR1 alloSCT) compared to non-CR1 alloSCT trended towards improved OS but did not reach significance (HR 0.56, 0.23-1.39, p=0.207).
After C2, most patients (31/36, 86%) still had detectable NUP98 fusion transcripts. A ≥3-log reduction from baseline was achieved in 14/31 (45%) and clearance below this threshold was associated with improved RFS (HR 0.27, 0.08-0.77, p=0.014) and OS (HR 0.17, 0.03-0.68, p=0.01).
Before CR1 alloSCT, 21/29 (72%) patients still had detectable MRD, however importantly, most of these patients became MRD negative after transplant: of patients who were MRD positive pre-CR1 alloSCT, 71% converted to MRD negative by D+100, and 84% converted to MRD negative at some point after transplant.
13/23 (57%) patients achieved a ≥3-log reduction in MRD prior to CR1 alloSCT, and this was associated with improved RFS (3-year RFS 88% vs 44%, HR 0.10, 0.01-0.85, p=0.01) and OS (3-year OS 100% vs 34%, HR 0.13, 0.02-1.11, p=0.028). 15/19 (79%) assessable patients had achieved MRD negativity by D+100 post-CR1 alloSCT with reduced relapse risk (3-year RFS 74% vs 25%, HR 0.13, 0.021-0.76, p=0.008).
Considering all patients who received a transplant, the ≥3-log reduction threshold remained prognostic prior to transplant (3-year OS 93% vs 42%, HR 0.17, 0.04-0.82, p=0.014) as did achievement of MRD negativity by D+100 post-SCT (3-year OS 80% vs 33%, HR 0.10, 0.014-0.54, p=0.008).
Conclusions
Here we show relatively favourable outcomes for patients with NUP98r AML with contemporary treatment protocols. We did not observe a survival benefit for treatment with GO or FLAG-ida. We show that molecular MRD monitoring provides powerful prognostic information, but that only a minority of patients achieve MRD-negativity after two cycles of chemotherapy or before transplant. Nevertheless, many of these patients clear MRD and become long-term survivors.
Although currently classified in the ELN intermediate-risk group these data suggest that patients with NUP98r AML would be better served using an adverse-risk treatment policy, where all eligible patients are taken to transplant regardless of their MRD status.
DISCLOSURES
Michael Lim, MBBS, MRCP (UK), FRCPath, PhD: No relevant conflicts of interest to declare.